PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has earned a consensus rating of “Hold” from the fifteen research ...

Dr. Jerome Zeldis and Dr. Blythe Sather bring exceptional backgrounds in cell therapy and solid tumorsCAMBRIDGE, Mass., Jan.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on PTC Therapeutics (PTCT – Research Report), ...

Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for PTC Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the ...

Larimar Therapeutics, Inc. (NASDAQ:LRMR), with a market capitalization of $228 million, is a clinical-stage biopharmaceutical ...

Novartis AG NVS, a Swiss pharma giant, is scheduled to report fourth-quarter 2024 and full-year results on Jan. 31, 2025. The ...

Subtle signs of neurodegeneration can be detected in blood, CSF, and neuroimaging, up to 20 years before the motor symptoms ...

More than two years after its approval in Europe, PTC Therapeutics' gene therapy for rare genetic disorder AADC deficiency will soon be made available to patients in the US. The FDA has approved ...

BIIB's regulatory filings are supported by late-stage data, which show that treatment with a higher Spinraza dose improves motor function in infants with SMA.

Novartis has made a dramatic return to the Huntington's disease therapy stage by licensing a candidate from PTC Therapeutics for a whopping $1 billion upfront. The deal – which has a potential ...

The breakthrough in AI technology by Chinese startup DeekSeek's r1 model has the potential to benefit the software sector, ...